3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Interventions
mirvetuximab soravtansine
2
Paclitaxel
2
sacituzumab govitecan
1
pembrolizumab
1
liposomal doxorubicin
1
Topotecan
1
Saline Solution
1
Glucose
1
Docetaxel
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Carcinoma, Ovarian Epithelial
×
mirvetuximab soravtansine
×
Clear all
NCT04209855
2025-08-27
MIRASOL
AbbVie
Phase 3
Completed
453 enrolled
18 charts
1 FDA
NCT04296890
2024-08-07
SORAYA
ImmunoGen, Inc.
Phase 3
Completed
106 enrolled
14 charts
1 FDA